Companies
8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗
INSM
INSMED Inc
INSMED Inc develops inhaled therapies for serious lung infections and diseases. The company has commercialized ARIKAYCE (amikacin liposome inhalation suspension) for treating certain respiratory infections and is working to commercialize BRINSUPRI in additional markets, while pursuing regulatory approvals to expand ARIKAYCE to broader patient populations. INSMED is in the commercial and late-stage clinical development phase, with marketed products in the U.S., Europe, and Japan.
$136.33+89.35%1Y
INSM · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Pulmonary Hypertension
Phase 3Interstitial Lung Disease
Phase 2/3Pulmonary Arterial Hypertension
Phase 2Hidradenitis Suppurativa
UnknownIndication pending review
UnknownIndication pending review
Catalyst Calendar
Past (9)
MAY 09
Readouttreprostinil palmitil inhalation powder (TPIP)
“the Company reported topline safety and tolerability data from its Phase 2 study of treprostinil palmitil inhalation powder ("TPIP") in patients with pulmonary hypertension associated with interstitial lung disease”
MAY 09
Interimtreprostinil palmitil inhalation powder (TPIP)
“provided an update on blinded data from its ongoing Phase 2 study of TPIP in pulmonary arterial hypertension”
MAY 28
Conf.Brensocatib
“The Company will host a conference call to discuss the positive topline results of the ASPEN study on May 28, 2024 at 8:00 a.m., Eastern Time”
H2
ReadoutBrensocatib
“the Company plans to initiate a Phase 2 study in hidradenitis suppurativa in the second half of 2024.”
Q4
NDABrensocatib
“Based on these results, the Company plans to file a New Drug Application with the U.S. Food and Drug Administration ("FDA") for brensocatib in patients with bronchiectasis in the fourth quarter of 2024.”
AUG 12
PDUFABrensocatib
“The FDA previously granted the Company's request for priority review and set a target action date of August 12, 2025 under the Prescription Drug User Fee Act.”
Q1
Enroll.treprostinil palmitil inhalation powder (TPIP)
“a Phase 3 trial in patients with PAH in early 2026”
MAR 23
ReadoutARIKAYCE
“On March 23, 2026, Insmed Incorporated (the "Company") issued a press release announcing positive topline results from its Phase 3b ENCORE study of ARIKAYCE® (amikacin liposome inhalation suspension) plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg) once-daily versus placebo plus multidrug therapy once-daily in diagnosed patients with a new occurrence of Mycobacterium avium complex ("MAC") lung infection who had not received antibiotics (the "ENCORE Study").”
MAR 23
Conf.ARIKAYCE
“The Company will host a conference call to discuss the positive topline results of the ENCORE Study on March 23, 2026, at 8:00 a.m., Eastern Time”